Novavax Inc NVAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
-
Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.
-
Novavax to Participate in Upcoming September Conferences
-
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
-
Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
-
Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
-
How the head of cannabis company Cronos dealt with a negative report from indicted short seller Andrew Left
-
Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,992
- Website
- https://www.novavax.com
Comparables
Valuation
|
Metric
|
NVAX
|
PCVX
|
02509
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 6.32 | 35.46 |
Price/Sales | 1.99 | — | 108.80 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NVAX
|
PCVX
|
02509
|
|---|---|---|---|
Quick Ratio | 0.93 | 17.75 | 1.70 |
Current Ratio | 1.04 | 17.88 | 1.86 |
Interest Coverage | −17.97 | — | −18.42 |
Quick Ratio
NVAX
PCVX
02509
Profitability
|
Metric
|
NVAX
|
PCVX
|
02509
|
|---|---|---|---|
Return on Assets (Normalized) | −14.68% | −20.76% | −47.40% |
Return on Equity (Normalized) | — | −22.15% | −341.08% |
Return on Invested Capital (Normalized) | — | −26.84% | −56.34% |
Return on Assets
NVAX
PCVX
02509
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fxkywdjbd | Fvhp | $566.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hzvqnczrr | Nqmqhx | $119.2 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dygmkfkpj | Psgngrx | $113.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hmsnqpr | Qgvkbq | $35.0 Bil | |||
| argenx SE ADR
ARGX
| Xlbpkdf | Fcvn | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Cbbmmkn | Ywg | $27.5 Bil | |||
| Moderna Inc
MRNA
| Ldyhnpkp | Hlgw | $24.5 Bil | |||
| United Therapeutics Corp
UTHR
| Kvkqvdgtk | Vvxnm | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hjshkndz | Dtdvzx | $13.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Ygyynkvy | Kqqpbbd | $12.4 Bil |
United States